Unknown

Dataset Information

0

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.


ABSTRACT: 177Lu-DOTA-HH1 (177Lu-HH1) is a novel anti-CD37 radioimmunoconjugate developed to treat non-Hodgkin lymphoma. Mice with subcutaneous Ramos xenografts were treated with different activities of 177Lu-HH1, 177Lu-DOTA-rituximab (177Lu-rituximab) and non-specific 177Lu-DOTA-IgG1 (177Lu-IgG1) and therapeutic effect and toxicity of the treatment were monitored. Significant tumor growth delay and increased survival of mice were observed in mice treated with 530 MBq/kg 177Lu-HH1 as compared with mice treated with similar activities of 177Lu-rituximab or non-specific 177Lu-IgG1, 0.9% NaCl or unlabeled HH1. All mice injected with 530 MBq/kg of 177Lu-HH1 tolerated the treatment well. In contrast, 6 out of 10 mice treated with 530 MBq/kg 177Lu-rituximab experienced severe radiation toxicity. The retention of 177Lu-rituximab in organs of the mononuclear phagocyte system was longer than for 177Lu-HH1, which explains the higher toxicity observed in mice treated with 177Lu-rituximab. In vitro internalization studies showed that 177Lu-HH1 internalizes faster and to a higher extent than 177Lu-rituximab which might be the reason for the better therapeutic effect of 177Lu-HH1.

SUBMITTER: Repetto-Llamazares AH 

PROVIDER: S-EPMC4466226 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.

Repetto-Llamazares Ada H V AH   Larsen Roy H RH   Patzke Sebastian S   Fleten Karianne G KG   Didierlaurent David D   Pichard Alexandre A   Pouget Jean Pierre JP   Dahle Jostein J  

PloS one 20150611 6


177Lu-DOTA-HH1 (177Lu-HH1) is a novel anti-CD37 radioimmunoconjugate developed to treat non-Hodgkin lymphoma. Mice with subcutaneous Ramos xenografts were treated with different activities of 177Lu-HH1, 177Lu-DOTA-rituximab (177Lu-rituximab) and non-specific 177Lu-DOTA-IgG1 (177Lu-IgG1) and therapeutic effect and toxicity of the treatment were monitored. Significant tumor growth delay and increased survival of mice were observed in mice treated with 530 MBq/kg 177Lu-HH1 as compared with mice tre  ...[more]

Similar Datasets

| S-EPMC7080250 | biostudies-literature
| S-EPMC6717602 | biostudies-literature
| S-EPMC4588185 | biostudies-literature
| S-EPMC9841868 | biostudies-literature
| S-EPMC4023679 | biostudies-literature
| S-EPMC3872218 | biostudies-other
| S-EPMC7655020 | biostudies-literature
2007-07-01 | GSE7322 | GEO
| S-EPMC7956426 | biostudies-literature
| S-EPMC8546323 | biostudies-literature